Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 16:7:61.
doi: 10.12688/f1000research.12433.1. eCollection 2018.

Early Detection and Chemoprevention of Lung Cancer

Melissa New  1 , Robert Keith  1   2   3
Affiliations
Review

Early Detection and Chemoprevention of Lung Cancer

Melissa New et al. F1000Res. .

Abstract

Despite advances in targeted treatments, lung cancer remains a common and deadly malignancy, in part owing to its typical late presentation. Recent developments in lung cancer screening and ongoing efforts aimed at early detection, treatment, and prevention are promising areas to impact the mortality from lung cancer. In the past several years, lung cancer screening with low-dose chest computed tomography (CT) was shown to have mortality benefit, and lung cancer screening programs have been implemented in some clinical settings. Biomarkers for screening, diagnosis, and monitoring of response to therapy are under development. Prevention efforts aimed at smoking cessation are as crucial as ever, and there have been encouraging findings in recent clinical trials of lung cancer chemoprevention. Here we review advancements in the field of lung cancer prevention and early malignancy and discuss future directions that we believe will result in a reduction in the mortality from lung cancer.

Keywords: cancer prevention; chemoprevention; lung cancer screening.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Robert Keith has a patent on the use of prostacyclin for the chemoprevention of cancer.No competing interests were disclosed.No competing interests were disclosed.

References

    1. American Cancer Society: Cancer Facts & Figures 2017. Atlanta: American Cancer Society;2017. Reference Source
    1. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. : Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92(16):1308–16. 10.1093/jnci/92.16.1308 - DOI - PubMed
    1. Marcus PM, Bergstralh EJ, Zweig MH, et al. : Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst. 2006;98(11):748–56. 10.1093/jnci/djj207 - DOI - PubMed
    1. Manser R, Lethaby A, Irving LB, et al. : Screening for lung cancer. Cochrane Database Syst Rev. 2013; (6): CD001991. 10.1002/14651858.CD001991.pub3 - DOI - PMC - PubMed
    1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. : Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. 10.1056/NEJMoa1102873 - DOI - PMC - PubMed

    2. F1000 Recommendation

LinkOut - more resources